morphictx.com (MORF): Net earnings per share for the last 12 months

MORF (Morphic Therapeutic) - company brandmark

The rolling annual earnings per share dynamics for Morphic Holding, Inc. (MORF) are based on the utilization of the MInT platform and the support of a major partner. The current metric value of -3.58 is being shaped by the release of inhibitors through contract organizations. However, the success of Morphic Holding, Inc. (MORF) depends on the outcomes of eltramzigab tests and the ability to raise capital to compete with biopharmaceutical market behemoths.

MORF Morphic Holding, Inc. Net earnings per share for the last 12 months (07/04/2022 - 08/24/2024)

Analytical breakdowns for Morphic Therapeutic (MORF)

- stock price and consensus target price:
Stock Price Morphic Holding, Inc.|MORF - Analyst Median Target
- stock exchange capitalization data:
Market Valuation Morphic Therapeutic|MORF - Aggregate Business Value
- balance sheet net asset value indicators:
Net Assets per Single Share Morphic|MORF - Company Net Assets|Market Value to Book Value Ratio morphictx.com|MORF - Company Assets
- business debt structure and liquidity details:
Debt to Equity Morphic Holding, Inc.|MORF - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Morphic Holding Inc|MORF - Company Aggregate Indebtedness|Debts to Book Capitalization Morphic Therapeutic|MORF - Company Long-Term Loans and Borrowings|Company Short-Term Debts Morphic|Quick Ratio morphictx.com
- earnings and multiples data:
MORF - Net Income|Future Profit Morphic Holding, Inc.|MORF - Company Value to Net Income|Forward P/E Multiple Morphic|MORF - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Morphic Therapeutic|MORF - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Morphic|MORF - Earnings per share for the last twelve months|Quarterly EPS earnings growth morphictx.com|MORF - Earnings per share growth this year|Earnings growth forecast for next year Morphic Holding, Inc.
- revenue and sales details:
MORF - Company Gross Revenue|Company Projected Revenue Morphic Holding, Inc.|MORF - Market Cap to Revenue Ratio|Forward P/S Multiple Morphic Therapeutic
Summary company analysis:Morphic Holding, Inc. (MORF)
Mass-produced product of Morphic Holding Inc

For Morphic Holding, Inc. (MORF), the current level of rolling earnings per share serves as an indicator of real business efficiency. This metric is calculated as the ratio of total annual net income to the number of outstanding securities. This indicator allows for an assessment of equity returns while excluding the influence of total capital volume. In the non-cyclical biotech sector, EPS dynamics depend directly on the progress of clinical trials. Stable profit growth confirms the commercial viability of the drugs under development.

Competing companies

Phathom Pharmaceuticals - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters ternspharma.com TERN|IRWD (ironwoodpharma.com) - Net earnings per share for the last 12 months|CURX: Earnings per share for the last four quarters|Earnings per share for the last twelve months Immuron Ltd|Net earnings per share for the last 12 months Evoke Pharma Inc (EVOK)|Earnings per share for the last twelve months Entero Therapeutics, Inc. (ENTO)|RDHL - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Palisade Bio, Inc. PALI|Earnings per share for the trailing year JAGX|BIOR - Earnings per share for the last twelve months